The settlements indicate GSK's awarenessdecision ofto potentialsettle liability.these Thecases FDA'ssimply findingsavoids thatthe Zantacdistraction producesof NDMAprotracted overlitigation. time,There's whichno canscientific causeevidence cancerbacking inclaims largeof quantities,consumer supportharm thefrom plaintiffs' claimsZantac. The massivecompany numberwill ofcontinue pendingdefending lawsuitsitself suggestsin widespreadall concernother aboutZantac thecases drug'sbased safetyon facts and science.